We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Innovative Mesh Implant Simplifies Soft Tissue Repair

By HospiMedica International staff writers
Posted on 16 Oct 2019
Image: A close-up of warp knitted mesh treated with ANAB technology (Photo courtesy of Exogensis).
Image: A close-up of warp knitted mesh treated with ANAB technology (Photo courtesy of Exogensis).
A proprietary hernia repair device employs surface nano-modification technology for the repair of abdominal wall hernia defects, including direct and indirect inguinal defects.

The Exogenesis (Billerica, MA, USA) Hernia Mesh is constructed of monofilament polypropylene (PP) fibers warp knitted together, and a unique nanometer-level surface texture achieved via accelerated neutral atom beam (ANAB) technology designed to enable favorable post-implant tissue compatibility. The PP knitting process creates large pores and minimum density and thickness, resulting in an implant, which allows tissue ingrowth and long-term tissue support, simultaneously minimizing the inflammatory response and fibrous encapsulation related to implant mass.

The mesh is also treated using the ANAB process to modify the surface of the filaments on a nanometer scale. The low-energy nano-scale surface modification is created by acceleration of neutral argon (Ar) atoms with very low energies under vacuum, which bombard the PP surface, modifying it to a shallow depth of 2-3 nm, causing modifications of surface topography, structure, and energy. Exogenesis Hernia Mesh is indicated for the repair of abdominal wall hernias and abdominal wall deficiencies, but is not indicated for transvaginal pelvic organ prolapse repair.

“ANAB surface treatment technology is already being deployed on other devices, however Exogenesis Hernia Mesh is our first proprietary product developed entirely in-house,” said Dmitry Shashkov, PhD, President and CEO of Exogenesis. “ANAB has the bioactive potential to improve medical device implant responses in man, and we are excited to bring this exciting technology one step closer to the clinical community.”

Surgical meshes have been in use since the late 19th century. In recent years, research in the area has increased due to increasing numbers of post-surgery complications such as infection, fibrosis, adhesions, mesh rejection, and hernia recurrence. A wide range of materials and coatings, meshes with different fiber thickness and porosity, a variety of manufacturing methods, as well as surgical and implantation procedures have been tested. Recently, surface modification methods and nanofiber-based systems are actively being explored as a pathway to increase biocompatibility.

Related Links:
Exogenesis

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
New
Shoulder System
Identity Shoulder System
New
Trocar
TAN RoTaLock Trocar

Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: A research collaboration aims to further advance findings in human genomics research in cardiovascular diseases (Photo courtesy of 123RF)

Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies

A research collaboration will focus on the joint discovery of novel therapeutic approaches based on findings in human genomics research related to cardiovascular diseases. Bayer (Berlin, Germany) and... Read more